Allergy Therapeutics (GB:AGY) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Allergy Therapeutics has commenced a pioneering Phase III trial to assess the long-term effectiveness and safety of its Grass MATA MPL immunotherapy in children with grass-induced allergic rhinitis. This trial marks a significant advancement following successful adult trials, aiming to offer a transformative treatment option with only six doses required before the allergy season. The trial’s success could potentially broaden the company’s market impact and appeal to investors keen on innovative biotech solutions.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
